
Opinion|Videos|February 21, 2025
Impact of Patient-Reported Outcomes and Real-World Evidence in CLL and MCL
Panelists discuss how patient-reported outcomes and real-world evidence influence clinical decision-making when selecting Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).
Advertisement
Episodes in this series

- How do patient-reported outcomes and real-world evidence influence your clinical decision-making process when selecting BTK inhibitor therapies for CLL and MCL?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
2
It’s Time to Reimagine Reimbursement for CAR T-Cell Therapy
3
What ACA Subsidy Expiration Means for Coverage Costs, Employer Strategy, and ICHRAs: Q&A With Ben Light
4
Fee-for-Service Models Linked to Higher Odds of Low-Value Surgical Procedures
5
















































